BR112013033098B8 - inibidores de glicosidade seletivos e usos dos mesmos - Google Patents
inibidores de glicosidade seletivos e usos dos mesmosInfo
- Publication number
- BR112013033098B8 BR112013033098B8 BR112013033098A BR112013033098A BR112013033098B8 BR 112013033098 B8 BR112013033098 B8 BR 112013033098B8 BR 112013033098 A BR112013033098 A BR 112013033098A BR 112013033098 A BR112013033098 A BR 112013033098A BR 112013033098 B8 BR112013033098 B8 BR 112013033098B8
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- glycosity
- inhibitors
- selective
- deficiency
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
- C07H9/06—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing nitrogen as ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Abstract
inibidores de glicosidade seletivos e uso dos mesmos. a invenção provê compostos com acentuada permeabilidade para seletivamente inibir glicosidases, profárrnacos dos compostos e composições farmacêuticas incluindo os compostos ou profárrnacos dos compostos. a invenção também provê métodos de tratar doenças e distúrbios relacionados com a deficiência ou superexpressão de o-glcnacase, acúmulo ou deficiência de o-glcnac.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161501377P | 2011-06-27 | 2011-06-27 | |
US61/501,377 | 2011-06-27 | ||
PCT/CA2012/050433 WO2013000084A1 (en) | 2011-06-27 | 2012-06-27 | Selective glycosidase inhibitors and uses thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112013033098A2 BR112013033098A2 (pt) | 2016-09-06 |
BR112013033098B1 BR112013033098B1 (pt) | 2020-10-20 |
BR112013033098B8 true BR112013033098B8 (pt) | 2021-03-23 |
Family
ID=47423333
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013033098A BR112013033098B8 (pt) | 2011-06-27 | 2012-06-27 | inibidores de glicosidade seletivos e usos dos mesmos |
Country Status (11)
Country | Link |
---|---|
US (1) | US9409924B2 (pt) |
EP (1) | EP2723753B1 (pt) |
JP (1) | JP6147737B2 (pt) |
KR (1) | KR102054744B1 (pt) |
CN (1) | CN103889996B (pt) |
AU (1) | AU2012276257B2 (pt) |
BR (1) | BR112013033098B8 (pt) |
CA (1) | CA2840013C (pt) |
MX (1) | MX364602B (pt) |
RU (1) | RU2625308C2 (pt) |
WO (1) | WO2013000084A1 (pt) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007291870B2 (en) | 2006-08-31 | 2012-12-06 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
JP5687194B2 (ja) | 2008-08-01 | 2015-03-18 | サイモン フレイザー ユニバーシティ | 選択的グリコシダーゼインヒビターおよびその使用 |
US9120781B2 (en) | 2010-05-11 | 2015-09-01 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
US8933040B2 (en) | 2010-11-08 | 2015-01-13 | Craig A. Coburn | Selective glycosidase inhibitors and uses thereof |
EP2655388B1 (en) | 2010-12-23 | 2016-06-08 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
EP2688899B1 (en) | 2011-03-24 | 2017-02-22 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
WO2012129651A1 (en) | 2011-03-31 | 2012-10-04 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
WO2013000085A1 (en) | 2011-06-27 | 2013-01-03 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
EP2723753B1 (en) | 2011-06-27 | 2017-08-02 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
WO2013000086A1 (en) | 2011-06-27 | 2013-01-03 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
US9809537B2 (en) | 2012-08-31 | 2017-11-07 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
US9670195B2 (en) | 2012-08-31 | 2017-06-06 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
BR112015009638A2 (pt) | 2012-10-31 | 2017-07-04 | Alectos Therapeutics Inc | inibidores de glicosidase e usos dos mesmos |
WO2014100934A1 (en) | 2012-12-24 | 2014-07-03 | Merck Sharp & Dohme Corp. | Glycosidase inhibitors and uses thereof |
KR102580225B1 (ko) | 2013-06-11 | 2023-09-20 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | SC-β 세포 및 조성물 그리고 그 생성 방법 |
AR106977A1 (es) * | 2015-12-14 | 2018-03-07 | Amicus Therapeutics Inc | Compuestos para el tratamiento de la enfermedad de alzheimer y/o la angiopatía amiloide cerebral |
WO2019151274A1 (ja) * | 2018-02-01 | 2019-08-08 | 日本たばこ産業株式会社 | 含窒素複素環アミド化合物及びその医薬用途 |
GB201907716D0 (en) | 2019-05-31 | 2019-07-17 | Smith & Nephew | Systems and methods for extending operational time of negative pressure wound treatment apparatuses |
GB202000274D0 (en) | 2020-01-09 | 2020-02-26 | Smith & Nephew | Systems and methods for monitoring operational lifetime of negative pressure wound treatment apparatuses |
US20240024565A1 (en) | 2020-10-05 | 2024-01-25 | T.J.Smith And Nephew,Limited | Temperature monitoring and control for negative pressure wound therapy systems |
GB202104922D0 (en) | 2021-04-07 | 2021-05-19 | Smith & Nephew | Temperature monitoring and control for negative pressure wound therapy systems |
KR102533471B1 (ko) | 2020-11-23 | 2023-05-19 | (주) 메디프론디비티 | O-GlcNAcase 저해 활성을 갖는 화합물 및 이의 용도 |
CA3222678A1 (en) | 2021-06-25 | 2022-12-29 | Allan Kenneth Frazer Grugeon HUNT | Liquid ingress protection and design of electronic circutry for negative pressure wound therapy systems |
GB202109154D0 (en) | 2021-06-25 | 2021-08-11 | Smith & Nephew | Liquid ingress protection for negative pressure wound therapy systems |
GB202110240D0 (en) | 2021-07-16 | 2021-09-01 | Smith & Nephew | Reduced pressure apparatuses and methods |
WO2023131680A1 (en) | 2022-01-10 | 2023-07-13 | T.J.Smith And Nephew,Limited | Temperature detection and protection for negative pressure wound therapy systems |
WO2023135177A1 (en) | 2022-01-14 | 2023-07-20 | T.J.Smith And Nephew, Limited | Self-calibration with dynamic therapy performance for negative pressure wound therapy devices |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU1441749A1 (ru) * | 1987-03-16 | 1996-01-10 | Институт Тонкой Органической Химии Им.А.Л.Мнджояна | 2-АМИНО-5,5-ДИМЕТИЛ-4,5-ДИГИДРО-7Н-ПИРАНО [4,3-d] ТИАЗОЛ, ОБЛАДАЮЩИЙ ТРАНКВИЛИЗИРУЮЩЕЙ АКТИВНОСТЬЮ |
JPH01180894A (ja) | 1988-01-07 | 1989-07-18 | Wako Pure Chem Ind Ltd | アミノ糖誘導体の新規な製造法 |
JPH07316178A (ja) | 1994-05-25 | 1995-12-05 | Sankyo Co Ltd | 糖アミノオキサゾリン類 |
JPH09132585A (ja) | 1995-11-10 | 1997-05-20 | Shin Etsu Chem Co Ltd | 新規アミノ糖及びキトオリゴ糖又はその類似オリゴ糖の製造方法 |
JP4233262B2 (ja) | 2001-03-14 | 2009-03-04 | 生化学工業株式会社 | カルバ糖アミン誘導体及びそれを用いるグリコシダーゼ阻害剤 |
JP4866515B2 (ja) | 2001-07-02 | 2012-02-01 | 生化学工業株式会社 | 糖オキサゾリン誘導体の製造方法 |
EP1734821A4 (en) | 2004-04-14 | 2011-07-06 | Uab Research Foundation | ACTIVATORS OF HEXOSAMIN BINOSYNTHESIS AS AN INHIBITORS FOR INDUCED DAMAGE CAUSED BY ISCHEMIC SHOCK OR HEMORRHAGIC SHOCK |
US20080287375A1 (en) | 2005-03-01 | 2008-11-20 | Simon Fraser University | Selective Glycosidase Inhibitors, Methods of Making Inhibitors, and Uses Thereof |
CN107253970A (zh) | 2006-08-31 | 2017-10-17 | 西蒙·弗雷瑟大学 | 选择性糖苷酶抑制剂及其用途 |
AU2007291870B2 (en) * | 2006-08-31 | 2012-12-06 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
US8541441B2 (en) | 2008-08-01 | 2013-09-24 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
JP5687194B2 (ja) | 2008-08-01 | 2015-03-18 | サイモン フレイザー ユニバーシティ | 選択的グリコシダーゼインヒビターおよびその使用 |
CA2737267A1 (en) | 2008-09-16 | 2010-04-08 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
US9120781B2 (en) | 2010-05-11 | 2015-09-01 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
US8933040B2 (en) | 2010-11-08 | 2015-01-13 | Craig A. Coburn | Selective glycosidase inhibitors and uses thereof |
TW201249848A (en) | 2010-11-08 | 2012-12-16 | Merck Sharp & Dohme | Selective glycosidase inhibitors and uses thereof |
WO2012061972A1 (en) * | 2010-11-08 | 2012-05-18 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
WO2012061971A1 (en) | 2010-11-08 | 2012-05-18 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
EP2655388B1 (en) * | 2010-12-23 | 2016-06-08 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
GB201103526D0 (en) | 2011-03-02 | 2011-04-13 | Summit Corp Plc | Selective glycosidase inhibitors and uses thereof |
EP2688899B1 (en) | 2011-03-24 | 2017-02-22 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
WO2012129802A1 (en) | 2011-03-31 | 2012-10-04 | Alectos Therapeutics Inc. | Pyrano[3,2-d]thiazol derivatives and uses as selective glycosidase inhibitors thereof |
WO2012129651A1 (en) | 2011-03-31 | 2012-10-04 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
WO2013000085A1 (en) | 2011-06-27 | 2013-01-03 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
WO2013000086A1 (en) | 2011-06-27 | 2013-01-03 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
EP2723753B1 (en) | 2011-06-27 | 2017-08-02 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
WO2013025452A1 (en) | 2011-08-18 | 2013-02-21 | Merck Sharp & Dohme Corp. | Selective glycosidase inhibitors and uses thereof |
DK2748171T3 (en) | 2011-08-25 | 2016-05-09 | Merck Patent Gmbh | PYRANO [3,2-D] [1,3] THIAZOL AS GLYCOSIDASE INHIBITORS |
JP6178843B2 (ja) | 2012-05-08 | 2017-08-09 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 透過性グリコシダーゼインヒビターおよびその用途 |
WO2014032187A1 (en) | 2012-08-31 | 2014-03-06 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
US9670195B2 (en) | 2012-08-31 | 2017-06-06 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
US20150299122A1 (en) | 2012-08-31 | 2015-10-22 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
US9809537B2 (en) | 2012-08-31 | 2017-11-07 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
BR112015009638A2 (pt) | 2012-10-31 | 2017-07-04 | Alectos Therapeutics Inc | inibidores de glicosidase e usos dos mesmos |
WO2014100934A1 (en) | 2012-12-24 | 2014-07-03 | Merck Sharp & Dohme Corp. | Glycosidase inhibitors and uses thereof |
-
2012
- 2012-06-27 EP EP12804294.2A patent/EP2723753B1/en active Active
- 2012-06-27 CN CN201280040350.XA patent/CN103889996B/zh active Active
- 2012-06-27 WO PCT/CA2012/050433 patent/WO2013000084A1/en active Application Filing
- 2012-06-27 AU AU2012276257A patent/AU2012276257B2/en active Active
- 2012-06-27 MX MX2014000258A patent/MX364602B/es active IP Right Grant
- 2012-06-27 CA CA2840013A patent/CA2840013C/en active Active
- 2012-06-27 BR BR112013033098A patent/BR112013033098B8/pt active Search and Examination
- 2012-06-27 US US14/129,177 patent/US9409924B2/en active Active
- 2012-06-27 JP JP2014517357A patent/JP6147737B2/ja active Active
- 2012-06-27 RU RU2014102232A patent/RU2625308C2/ru active
- 2012-06-27 KR KR1020147001472A patent/KR102054744B1/ko active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
AU2012276257A1 (en) | 2014-01-23 |
MX2014000258A (es) | 2014-09-01 |
EP2723753B1 (en) | 2017-08-02 |
CN103889996B (zh) | 2016-02-03 |
JP6147737B2 (ja) | 2017-06-14 |
CN103889996A (zh) | 2014-06-25 |
RU2014102232A (ru) | 2015-08-10 |
CA2840013A1 (en) | 2013-01-03 |
CA2840013C (en) | 2021-02-09 |
KR20140043125A (ko) | 2014-04-08 |
RU2625308C2 (ru) | 2017-07-13 |
BR112013033098B1 (pt) | 2020-10-20 |
US20140296205A1 (en) | 2014-10-02 |
US9409924B2 (en) | 2016-08-09 |
JP2014524911A (ja) | 2014-09-25 |
KR102054744B1 (ko) | 2019-12-11 |
AU2012276257B2 (en) | 2017-05-18 |
BR112013033098A2 (pt) | 2016-09-06 |
EP2723753A1 (en) | 2014-04-30 |
MX364602B (es) | 2019-05-02 |
EP2723753A4 (en) | 2014-11-26 |
WO2013000084A1 (en) | 2013-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013033098B8 (pt) | inibidores de glicosidade seletivos e usos dos mesmos | |
BR112013011441A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
TN2013000348A1 (en) | Compounds and compositions as trk inhibitors | |
BR112019001607A2 (pt) | inibidores macrocíclicos de quinases | |
BR112015009638A2 (pt) | inibidores de glicosidase e usos dos mesmos | |
CY1118157T1 (el) | Εκλεκτικοι αναστολεις γλυκοσιδασης και χρησεις αυτων | |
BR112013027774A2 (pt) | novos compostos como moduladores de proteína quinases | |
EA201400772A1 (ru) | Варианты полипептидов ph20, композиции на их основе и их применение | |
UY33597A (es) | Compuestos y composiciones como inhibidores de la trk | |
BR112015000704A2 (pt) | imidazotriazinacarbonitrilas úteis como inibidores de quinase | |
EA201390711A1 (ru) | Гидроксиамидные соединения пиримидина в качестве ингибиторов деацетилаз белков и способы их применения | |
MX2014004766A (es) | Inhibidores de arginasa y sus aplicaciones terapeuticas. | |
MX339937B (es) | Compuestos y composiciones como inhibidores de la quinasa c-kit. | |
MX342329B (es) | Compuestos y composiciones como inhibidores de la quinasa c-kit. | |
PH12015500689A1 (en) | Azaquinazoline inhibitors of atypical protein kinase c | |
BR112014003681A2 (pt) | composto, composição farmacêutica, produto de combinação farmacêutica, uso de um composto, e, método para tratar doenças ou condições | |
BR112015012536A2 (pt) | tratamento de câncer com inibidores heterocíclicos da glutaminase | |
MX2014002486A (es) | Compuestos y composiciones como inhibidores de cinasa pdgfr. | |
MX355088B (es) | Inhibidores de tienopirimidina de proteina cinasa c atipica. | |
EA201492040A1 (ru) | Бициклически замещённые урацилы и их применение | |
EA201590962A1 (ru) | Новые соединения | |
EA201692313A1 (ru) | Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ | |
ECSP16008797A (es) | Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos | |
UY35747A (es) | Derivados sustituidos de fenilalanina | |
EA201491227A1 (ru) | Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law | ||
B06F | Objections, documents and/or translations needed after an examination request according art. 34 industrial property law | ||
B07E | Notice of approval relating to section 229 industrial property law |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure | ||
B06A | Notification to applicant to reply to the report for non-patentability or inadequacy of the application according art. 36 industrial patent law | ||
B09A | Decision: intention to grant | ||
B16A | Patent or certificate of addition of invention granted |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/06/2012, OBSERVADAS AS CONDICOES LEGAIS. |
|
B09W | Decision of grant: rectification |
Free format text: REFERENCIA: RPI 2583 DE 07.07.2020 - CODIGO 9.1 |
|
B16C | Correction of notification of the grant |
Free format text: REF. RPI 2598 DE 20/10/2020 QUANTO AS REIVINDICACOES. |